A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSV¿G-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Lambaréné, Gabon.

Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSV¿G-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Lambaréné, Gabon.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs RVSV-S-GP/VP40 vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2015 Status changed from planning to recruiting, as reported in a Public Health Agency of Canada media release.
    • 02 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top